TL;DR: The Centers for Medicare & Medicaid Services modified NCD 201 governing percutaneous transluminal angioplasty (PTA) coverage, with an effective date of March 7, 2026. Here's what billing teams need to do.
This update to the CMS PTA coverage policy expands and clarifies covered indications under NCD 201 Medicare—most notably adding explicit criteria for carotid artery stenting (CAS) with defined stenosis thresholds, mandatory neurological assessment requirements, and specific imaging protocols. The policy does not list specific CPT or HCPCS codes in this version. Your billing team needs to map these clinical criteria to your charge capture and documentation workflows before March 7, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Percutaneous Transluminal Angioplasty (PTA) |
| Policy Code | NCD 201 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | High |
| Specialties Affected | Interventional Radiology, Vascular Surgery, Interventional Cardiology, Nephrology, Neurology, Cardiovascular Surgery |
| Key Action | Audit documentation workflows for carotid artery stenting cases to confirm neurological assessment, duplex ultrasound, and CTA/MRA criteria are captured before billing |
CMS Percutaneous Transluminal Angioplasty Coverage Criteria and Medical Necessity Requirements 2026
The CMS PTA coverage policy under NCD 201 covers balloon angioplasty across several vascular territories. The procedure—inserting a balloon catheter into a narrowed or occluded vessel to restore blood flow—has been covered for decades. This modification sharpens the medical necessity criteria, particularly around carotid artery work.
Here's how coverage breaks down by indication.
Peripheral and Upper Extremity Arterial Disease
CMS covers PTA for atherosclerotic obstructive lesions in the lower extremities. That includes the iliac, femoral, and popliteal arteries. For upper extremities, coverage applies to the innominate, subclavian, axillary, and brachial arteries.
Head and neck vessels are explicitly excluded from the upper extremity category. Don't bill PTA of head or neck vessels under this peripheral indication—that's a different coverage pathway.
Coronary Artery Disease
PTA of a single coronary artery is covered, but only under specific conditions. The patient must meet all three of these criteria:
| # | Covered Indication |
|---|---|
| 1 | Angina refractory to optimal medical management |
| 2 | Objective evidence of myocardial ischemia |
| 3 | Lesions amenable to angioplasty |
The patient must also be someone for whom coronary bypass surgery is the likely alternative. This isn't broad coverage for any coronary lesion. If documentation doesn't support all three criteria, expect a claim denial.
Renal Artery Disease
For renal artery PTA, medical necessity requires that the patient has not responded adequately to thorough medical management of symptoms. CMS also requires that surgery be the likely alternative. The policy is explicit: PTA here is an alternative to surgery, not simply an addition to medical management.
This distinction matters for documentation. Your physicians need to record failed medical management and why surgery is the alternative—not just note that PTA was performed.
Arteriovenous Dialysis Fistulas and Grafts
PTA of arteriovenous dialysis fistulas and grafts is covered when performed through either a venous or arterial approach. This applies to your nephrology and dialysis access billing teams. Document the approach clearly—venous or arterial—in the procedure note.
Carotid Artery Stenting — The High-Stakes Change in This Update
The most significant change in this version of the coverage policy is the October 11, 2023 expansion now codified in NCD 201. CMS covers PTA of the carotid artery concurrent with stenting when all of the following conditions are met.
Patient eligibility (either A or B):
| # | Covered Indication |
|---|---|
| 1 | Symptomatic carotid artery stenosis ≥50% |
| 2 | Asymptomatic carotid artery stenosis ≥70% |
Procedural requirements (apply to both A and B):
| # | Covered Indication |
|---|---|
| 1 | Neurological assessment by a neurologist or NIH Stroke Scale (NIHSS)-certified health professional before and after CAS |
| 2 | First-line evaluation of carotid artery stenosis must use duplex ultrasound |
| 3 | Computed tomography angiography (CTA) or magnetic resonance angiography (MRA), if not contraindicated, must confirm the degree of stenosis |
The device requirements are also specific. CAS must use an FDA-approved carotid stent with an FDA-approved or FDA-cleared embolic protection device. Missing either device requirement removes the coverage basis entirely.
This is a significant documentation burden. You need pre- and post-procedure neurological assessments, duplex ultrasound reports, and CTA or MRA confirmatory imaging in the record before you submit a claim. Auditing your carotid procedure documentation now—before March 7, 2026—will save you from retroactive denials.
If your facility has questions about whether your existing CAS protocols satisfy these requirements, loop in your compliance officer and medical director before the effective date.
CMS PTA Exclusions and Non-Covered Indications
CMS does not cover PTA of the carotid artery outside the three specific pathways defined in NCD 201:
| # | Excluded Procedure |
|---|---|
| 1 | FDA-approved Category B IDE clinical trials (effective July 1, 2001) |
| 2 | FDA-approved post-approval studies with an FDA-approved carotid stent and embolic protection device (effective October 12, 2004) |
| 3 | The general coverage expansion with defined stenosis thresholds (effective October 11, 2023) |
Carotid PTA billed outside these pathways is not covered. Period. If your team is billing carotid angioplasty without concurrent stenting, or without the required embolic protection device, those claims will not pass medical necessity review.
PTA of head or neck vessels billed as upper extremity peripheral arterial disease is also not supported under NCD 201. The policy draws a clear line at "upper extremities do not include head or neck vessels."
Standalone PTA of the carotid artery—performed purely for dilation without concurrent stent placement—is only considered reasonable and necessary in the context of an IDE clinical trial or post-approval study.
Coverage Indications at a Glance
| Indication | Status | Stenosis Threshold | Key Requirements | Notes |
|---|---|---|---|---|
| Lower extremity arterial disease (iliac, femoral, popliteal) | Covered | N/A | Medical necessity documentation | Standard peripheral PTA |
| Upper extremity arterial disease (innominate, subclavian, axillary, brachial) | Covered | N/A | Medical necessity documentation | Head/neck vessels excluded |
| Single coronary artery — refractory angina | Covered | N/A | Refractory angina + objective ischemia + amenable lesion; bypass surgery as likely alternative | All three criteria required |
| Renal artery — inadequate response to medical management | Covered | N/A | Failed medical management; surgery as likely alternative | Not additive to medical management |
| AV dialysis fistulas and grafts | Covered | N/A | Venous or arterial approach | Document approach in procedure note |
| Carotid artery — symptomatic, concurrent with stenting (IDE trial) | Covered | N/A | FDA-approved Category B IDE protocol | Effective July 1, 2001 |
| Carotid artery — concurrent with stenting (post-approval study) | Covered | N/A | FDA-approved stent + embolic protection device; FDA-approved post-approval study protocol | Effective October 12, 2004 |
| Carotid artery — symptomatic, concurrent with stenting (general coverage) | Covered | ≥50% symptomatic | Pre/post neuro assessment; duplex ultrasound first-line; CTA or MRA confirmation; FDA-approved stent + embolic protection device | Effective October 11, 2023 |
| Carotid artery — asymptomatic, concurrent with stenting (general coverage) | Covered | ≥70% asymptomatic | Pre/post neuro assessment; duplex ultrasound first-line; CTA or MRA confirmation; FDA-approved stent + embolic protection device | Effective October 11, 2023 |
| Carotid PTA without concurrent stenting (outside trial/study) | Not Covered | N/A | N/A | No standalone carotid dilation outside protocol |
| PTA of head or neck vessels billed as upper extremity | Not Covered | N/A | N/A | Explicitly excluded from peripheral coverage |
CMS Percutaneous Transluminal Angioplasty Billing Guidelines and Action Items 2026
The modified NCD 201 creates real documentation and billing exposure for programs doing high-volume carotid and renal PTA work. Here are the steps your team should take now.
| # | Action Item |
|---|---|
| 1 | Audit your carotid PTA documentation templates before March 7, 2026. Your procedure notes, pre-op assessments, and imaging reports must show: neurological assessment (pre and post) by a neurologist or NIHSS-certified professional, duplex ultrasound as first-line imaging, and CTA or MRA confirmation of stenosis degree. If your templates don't capture all three, update them now. |
| 2 | Verify device documentation for every CAS case. The stent must be FDA-approved for the carotid indication. The embolic protection device must be FDA-approved or FDA-cleared. Pull your device inventory and confirm your procedure documentation records both device approvals. A missing embolic protection device notation is a claim denial waiting to happen. |
| 3 | Review your coronary PTA documentation for the three-criteria standard. Every coronary artery PTA claim needs evidence of refractory angina despite optimal medical management, objective evidence of myocardial ischemia, and lesion amenability. Train your cardiology documentation team on these three checkpoints. |
| 4 | Update your renal artery PTA records to show failed medical management. The policy requires that medical management was tried and failed before PTA. Document the specific medications, duration, and clinical response—or lack thereof. Also document why surgery is the likely alternative. Vague notes won't hold up in a medical necessity review. |
| 5 | Clarify your prior authorization workflows for carotid procedures. While NCD 201 itself does not specify prior authorization requirements, CAS procedures carry high financial exposure and often trigger pre-claim review. Confirm with your Medicare Administrative Contractor (MAC) whether any local coverage determination (LCD) or pre-claim review requirement applies in your jurisdiction. Regional MAC policies can add requirements beyond what the NCD states. |
| 6 | Confirm your PTA billing team knows the head/neck vessel exclusion. If anyone on your team has been coding carotid or cervical vessel PTA under the upper extremity peripheral arterial disease indication, that's a billing error. Correct it now and review any claims submitted in the last 12 months. |
| 7 | Flag carotid PTA cases in clinical trials separately. Cases performed under FDA-approved Category B IDE protocols or post-approval studies follow a different documentation and billing pathway. Make sure your coding team distinguishes these from general coverage cases—the reimbursement and documentation requirements differ. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Percutaneous Transluminal Angioplasty Under NCD 201
A Note on Codes
This version of NCD 201 does not list specific CPT or HCPCS codes. CMS has not enumerated procedure codes within the policy document itself. Your PTA angioplasty billing team should work with your coding team to map the covered indications to the appropriate CPT codes from the cardiovascular surgery, interventional radiology, and dialysis access sections of the CPT manual.
Common code families your coders will reference for PTA billing include peripheral vascular intervention codes, coronary intervention codes, renal artery intervention codes, and dialysis access intervention codes—but confirm the specific codes against your MAC's local coverage determination and current CPT guidelines. Do not rely on this post for code selection. If you're unsure which codes apply to your specific case mix, talk to your billing consultant before the March 7, 2026 effective date.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.